Connor, Clark & Lunn Investment Management (CC&L)’s Esperion Therapeutics ESPR Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-822,618	Closed	-$1.18M	–	1550
2025 Q1	$1.18M	Sell	822,618 -109,390	-12%	-$202K	0.01%	891
2024 Q4	$2.05M	Buy	932,008 +220,730	+31%	+$515K	0.01%	718
2024 Q3	$1.17M	Buy	711,278 +295,378	+71%	+$596K	0.01%	831
2024 Q2	$923K	Buy	+415,900	New	+$978K	﹤0.01%	867
2024 Q1	–	Sell	-352,054	Closed	-$1.05M	–	1569
2023 Q4	$1.05M	Sell	352,054 -61,650	-15%	-$80K	﹤0.01%	849
2023 Q3	$405K	Buy	413,704 +225,767	+120%	+$327K	﹤0.01%	1075
2023 Q2	$261K	Sell	187,937 -51,602	-22%	-$72.1K	﹤0.01%	1139
2023 Q1	$381K	Sell	239,539 -44,007	-16%	-$227K	﹤0.01%	959
2022 Q4	$1.77M	Buy	283,546 +132,042	+87%	+$944K	0.01%	571
2022 Q3	$1.01M	Buy	+151,504	New	+$1.04M	0.01%	652
2019 Q4	–	Sell	-22,262	Closed	-$816K	–	975
2019 Q3	$816K	Buy	22,262 +9,125	+69%	+$361K	0.01%	579
2019 Q2	$611K	Sell	13,137 -31,088	-70%	-$1.46M	﹤0.01%	681
2019 Q1	$1.78M	Buy	44,225 +1,825	+4%	+$81.9K	0.01%	435
2018 Q4	$1.95M	Buy	42,400 +950	+2%	+$45.8K	0.01%	423
2018 Q3	$1.84M	Sell	41,450 -15,875	-28%	-$729K	0.01%	448
2018 Q2	$2.25M	Buy	+57,325	New	+$2.9M	0.01%	450
2015 Q2	–	Sell	-6,500	Closed	-$602K	–	627
2015 Q1	$602K	Buy	+6,500	New	+$419K	0.01%	375